ArticleTherapeutic advances in neurological disorders2018

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.

Douglas L Arnold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.